Show simple item record

dc.contributor.authorTaylor, Amy Een
dc.contributor.authorMartin, Richard Men
dc.contributor.authorGeybels, Milan Sen
dc.contributor.authorStanford, Janet Len
dc.contributor.authorShui, Ireneen
dc.contributor.authorEeles, Rosalinden
dc.contributor.authorEaston, Douglasen
dc.contributor.authorKote-Jarai, Zsofiaen
dc.contributor.authorAmin Al Olama, Alien
dc.contributor.authorBenlloch, Saraen
dc.contributor.authorMuir, Kennethen
dc.contributor.authorGiles, Graham Gen
dc.contributor.authorWiklund, Fredriken
dc.contributor.authorGronberg, Henriken
dc.contributor.authorHaiman, Christopher Aen
dc.contributor.authorSchleutker, Johannaen
dc.contributor.authorNordestgaard, Børge Gen
dc.contributor.authorTravis, Ruth Cen
dc.contributor.authorNeal, Daviden
dc.contributor.authorPashayan, Noraen
dc.contributor.authorKhaw, Kay-Teeen
dc.contributor.authorBlot, Williamen
dc.contributor.authorThibodeau, Stephenen
dc.contributor.authorMaier, Christianeen
dc.contributor.authorKibel, Adam Sen
dc.contributor.authorCybulski, Cezaryen
dc.contributor.authorCannon-Albright, Lisaen
dc.contributor.authorBrenner, Hermannen
dc.contributor.authorPark, Jongen
dc.contributor.authorKaneva, Radkaen
dc.contributor.authorBatra, Jyotsnaen
dc.contributor.authorTeixeira, Manuel Ren
dc.contributor.authorPandha, Hardeven
dc.contributor.authorand, the PRACTICAL Consortiumen
dc.contributor.authorDonovan, Jennyen
dc.contributor.authorMunafò, Marcus Ren
dc.date.accessioned2016-10-26T13:35:38Z
dc.date.available2016-10-26T13:35:38Z
dc.date.issued2016-10-26en
dc.identifier.issn0020-7136
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/260919
dc.description.abstractCoffee consumption has been shown in some studies to be associated with lower risk of prostate cancer. However, it is unclear if this association is causal or due to confounding or reverse causality. We conducted a Mendelian randomisation analysis to investigate the causal effects of coffee consumption on prostate cancer risk and progression. We used two genetic variants robustly associated with caffeine intake (rs4410790 and rs2472297) as proxies for coffee consumption in a sample of 46,687 men of European ancestry from 25 studies in the PRACTICAL consortium. Associations between genetic variants and prostate cancer case status, stage and grade were assessed by logistic regression and with all-cause and prostate cancer-specific mortality using Cox proportional hazards regression. There was no clear evidence that a genetic risk score combining rs4410790 and rs2472297 was associated with prostate cancer risk (OR per additional coffee increasing allele: 1.01, 95% CI: 0.98,1.03) or having high-grade compared to low-grade disease (OR: 1.01, 95% CI: 0.97,1.04). There was some evidence that the genetic risk score was associated with higher odds of having nonlocalised compared to localised stage disease (OR: 1.03, 95% CI: 1.01, 1.06). Amongst men with prostate cancer, there was no clear association between the genetic risk score and all-cause mortality (HR: 1.00, 95% CI: 0.97,1.04) or prostate cancer-specific mortality (HR: 1.03, 95% CI: 0.98,1.08). These results, which should have less bias from confounding than observational estimates, are not consistent with a substantial effect of coffee consumption on reducing prostate cancer incidence or progression.
dc.description.sponsorshipBritish Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, and the National Institute for Health Research, under the auspices of the UK Clinical Research Collaboration Cancer Research UK. Grant Number: C18281/A19169 RMM and Caroline Relton (Integrative Cancer Epidemiology Programme) Canadian Institutes of Health Research the European Commission's Seventh Framework Programme. Grant Numbers: 223175, HEALTH-F2-2009-223175 Cancer Research UK. Grant Numbers: C5047/A7357, C1287/A10118, C5047/A3354, C5047/A10692, C16913/A6135 National Institute of Health (NIH) Cancer Post-Cancer GWAS. Grant Number: 1 U19 CA 148537-01 the GAME-ON initiative the European Community's Seventh Framework Programme. Grant Numbers: 223175, HEALTH-F2-2009-223175 Cancer Research UK. Grant Numbers: C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692 the National Institutes of Health. Grant Number: CA128978 Post-Cancer GWAS initiative. Grant Numbers: 1U19 CA148537, 1U19 CA148065, 1U19 CA148112 the GAME-ON initiative the Department of Defence. Grant Number: W81XWH-10-1-0341 the Canadian Institutes of Health Research (CIHR) CIHR Team in Familial Risks of Breast Cancer Komen Foundation for the Cure Breast Cancer Research Foundation. Grant Number: Ovarian Cancer Research Fund VicHealth and Cancer Council Victoria Australian NHMRC. Grant Numbers: 209057, 251553, 504711 Cancer Council Victoria Australian Institute of Health and Welfare (AIHW) National Death Index and the Australian Cancer Database U.K. Health Technology Assessment (HTA) Programme of the NIH Research. Grant Numbers: HTA 96/20/99, ISRCTN20141297 Prodigal study and the ProMPT (Prostate Mechanisms of Progression and Treatment) National Cancer Research Institute (NCRI) Department of Health, the Medical Research Council and Cancer Research UK. Grant Number: G0500966/75466 Cancer Research UK. Grant Number: C5047/A7357 NIHR Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust National Institute for Health Research Bristol Nutrition Biomedical Research Unit based at University Hospitals Bristol NHS Foundation Trust and the University of Bristol FCH, DEN and JLD are NIHR Senior Investigators MRC and the University of Bristol. Grant Numbers: G0600705, MC_UU_12013/6
dc.languageEnglishen
dc.language.isoenen
dc.publisherWiley
dc.rightsAttribution 4.0 International
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectprostate canceren
dc.subjectcoffeeen
dc.subjectMendelian randomizationen
dc.titleInvestigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysisen
dc.typeArticle
dc.description.versionThis is the final version of the article. It first appeared from Wiley via https://doi.org/10.1002/ijc.30462en
prism.publicationDate2016en
prism.publicationNameInternational Journal of Canceren
dc.identifier.doi10.17863/CAM.6094
dcterms.dateAccepted2016-09-05en
rioxxterms.versionofrecord10.1002/ijc.30462en
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2016-10-26en
dc.contributor.orcidEaston, Douglas [0000-0003-2444-3247]
dc.contributor.orcidAmin Al Olama, Ali [0000-0002-7178-3431]
dc.contributor.orcidKhaw, Kay-Tee [0000-0002-8802-2903]
dc.identifier.eissn1097-0215
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMEDICAL RESEARCH COUNCIL (MR/N003284/1)
pubs.funder-project-idMRC (G1000143)
pubs.funder-project-idMRC (G0401527)
pubs.funder-project-idNational Cancer Institute (NCI) (U19CA148537)
pubs.funder-project-idNational Cancer Institute (NCI) (R01CA128978)
pubs.funder-project-idCancer Research UK (CRUK-A12014)
pubs.funder-project-idCancer Research UK (CRUK-A10118)
cam.orpheus.successThu Jan 30 12:57:24 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International